HARMONi-2 shows ivonescimab improved median OS to 30.8 months versus 22.6 months with pembrolizumab in first-line ...

ABC8 Guidelines update advanced breast cancer care with new biomarker, ADC, endocrine, HER2, TNBC, exercise and ...

FDA Approves Taletrectinib Label Update With 49.7-Month Duration of Response in ROS1+ NSCLC / cancer, clinical trials, FDA ...

I Am Pleased to Announce UT MD Anderson’s 2026 Class of ECHO Scholars / Ana Refinetti, cancer, ECHO Scholars, ECHO Scholars ...

Lessons in Global Oncology and Access to Cancer Care / AIIMS New Delhi, cancer, OncoDaily, Oncoffee, Oncology, Vahe Grigoryan ...

What If We Are Missing Low-Level Targets That Are Rapidly Internalized? / ADC, Anton Safonov, Atif Ali Hashmi, Bo Liu, Bob Li ...

Can the gut microbiome shape response to cancer immunotherapy? Explore evidence linking gut bacteria, diet, antibiotics, FMT, ...

Reflecting on Eight Years of Service on Qatar’s National Cancer Governance Board / cancer, cancer care, Cancer Control, ...

Nivolumab With deb-TACE in Liver-Limited Hepatocellular Carcinoma / cancer, cancer care, Cancer research, cancer treatment, ...

We Hosted a Wonderful Dinner Prior to Our Debbie's Dream Foundation / Amanda Pullinger, Anil Nagar, Bill Unwin, cancer, ...

Mendus Initiates Phase 1b DIVA Trial of Vididencel Plus Venetoclax and Azacitidine in Acute Myeloid Leukemia / Acute Myeloid ...

Hesham ElGhazaly Named Candidate for UICC Board of Directors 2026–2028 / cancer, Hesham ElGhazaly, OncoDaily, Oncology, UICC, ...